Biocon Limited has informed the Exchange regarding a press release dated March 07, 2025, titled "Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek Biosimilar to Ustekinumab for Chronic Plaque Psoriasis".
Biocon Limited has informed the Exchange regarding a press release dated March 07, 2025, titled "Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek Biosimilar to Ustekinumab for Chronic Plaque Psoriasis".